Noxopharm Limited (ASX:NOX) (‘Noxopharm’ or the ‘Company’) is pleased in response to shareholder enquiry to provide some context around its recent announcement of Veyonda? and its stimulatory effects on the immune system. That context is in relation to the direction currently being taken in the development of the next generation of anti-cancer drugs.
For more information, download the attached PDF.
Download this document
